Kura Oncology (NASDAQ:KURA) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Thursday.
A number of other research firms also recently issued reports on KURA. Wedbush initiated coverage on Kura Oncology in a research report on Wednesday, December 20th. They set an “outperform” rating and a $19.00 price target for the company. Oppenheimer set a $18.00 price target on Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 11th. Citigroup boosted their price objective on Kura Oncology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. Cann restated a “buy” rating and set a $17.50 price objective on shares of Kura Oncology in a research note on Monday, December 11th. Finally, ValuEngine cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $21.67.
Shares of Kura Oncology (NASDAQ KURA) opened at $22.75 on Thursday. Kura Oncology has a 1 year low of $5.90 and a 1 year high of $24.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48. The stock has a market capitalization of $669.28, a PE ratio of -14.68 and a beta of 4.94.
Several institutional investors and hedge funds have recently modified their holdings of KURA. New York State Common Retirement Fund acquired a new position in shares of Kura Oncology during the second quarter worth about $142,000. MetLife Investment Advisors LLC acquired a new position in shares of Kura Oncology during the fourth quarter worth about $155,000. American International Group Inc. lifted its stake in shares of Kura Oncology by 42.0% during the fourth quarter. American International Group Inc. now owns 13,574 shares of the company’s stock worth $208,000 after purchasing an additional 4,012 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in shares of Kura Oncology during the second quarter worth about $226,000. Finally, California State Teachers Retirement System acquired a new position in shares of Kura Oncology during the second quarter worth about $235,000. Institutional investors own 62.83% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/24/bidaskclub-upgrades-kura-oncology-kura-to-strong-buy.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.